Cytarabine and daunorubicin liposomal (Vyxeos)
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Mechanism of action
This drug is a liposomal formulation of Cytarabine (Ara-C) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. [1][2][3]
Route: IV
Extravasation: no information
Disease for which it is established
History of changes in FDA indication
- 2017-08-03: Granted FDA regular approval for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. (Based on CLTR0310-301)
History of changes in EMA indication
- 2018-08-23: Initial authorization
Patient Information
Also known as
- Code name: CPX-351
- Brand name: Vyxeos, Vyxeos liposomal